ctDNA improves prognostic prediction in relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone.
Kogure Y, Handa H, Ito Y, Ri M, Horigome Y, Iino M, Harazaki Y, Kobayashi T, Abe M, Ishida T, Ito S, Iwasaki H, Kuroda J, Shibayama H, Sunami K, Takamatsu H, Tamura H, Hayashi T, Akagi K, Shinozaki T, Yoshida T, Mori I, Iida S, Maeda T, Kataoka K.
Kogure Y, et al. Among authors: yoshida t.
Blood. 2024 Mar 1:blood.2023022540. doi: 10.1182/blood.2023022540. Online ahead of print.
Blood. 2024.
PMID: 38427753
Free article.